Dr Reddy's Laboratories will soon enhance its existing manufacturing capacities and add new production lines to meet the growing international demand for generics and Customs Pharmaceutical Services.

Within the first half of 2006-07, the company will have a capacity to produce over 10 billion tablets and capsules. In future, the company is expected to ramp up the production of API and finished dosages, sources said.

Five of the company's seven key NCEs have advanced to clinical development and a few in pre-clinical stage. In addition, Dr Reddy's has strengthened its generics and API pipelines. In 2005-06, DRL filed 12 ANDAs taking the total number of ANDA filings to 70.

As on March 31, 2006, the company's US generics pipeline comprised 49 ANDAs pending with US FDA, including 29 Para IVs. The company increased the number of DMFs to 30, of which, 17 were US, eight Canadian, and five European. The total number of DMFs now stand at 15, 181 filed in the US, 28 in Canada and 42 in Europe.

The company expects to increase its revenues in the US generics segment driven by the launch of several new products in the current fiscal in addition to the full year of consolidation of financials of the acquisitions of Germany-based Betapharm and Roche's API business in Mexico.